// App-Quantinova.ai

2500 : Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

Researchers

Presenter

  • David Michael Hyman

Principal Investigators

  • Jesus Corral Jaime

  • Elena Garralda

  • Jean-Pascal H. Machiels

  • Jan H. M. Schellens

  • Phillipe Bedard

  • Mario Campone

  • Philippe Cassier

  • John Sarantopoulos

  • Ulka N. Vaishampayan

  • Rashmi Chugh

  • Amit Mahipal

  • Albert C. Lockhart

  • Cristiana Sessa

  • Thomas Zander

  • Matthew Ng

  • Giuseppe Curigliano

  • Jennifer Bendiske

  • Jose Manuel Perez-Garcia

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Royal Melbourne Hospital, Melbourne, Australia

  • Hospital Virgen del Rocio, Sevilla, Spain

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • Universite Catholique de Louvain Cliniques Universitaires St-Luc, Brussels, Belgium

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Cancer Institute of the West (ICO), Centre Rene Gauducheau, Medical Oncology Department, Saint-Herblain, France

  • Centre Leon Berard and Claude Bernard University, Lyon, France

  • Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center San Antonio, San Antonio, TX

  • Karmanos Cancer Institute, Detroit, MI

  • University of Michigan, Ann Arbor, MI

  • Moffitt Cancer Center, Tampa, FL

  • Washington University School of Medicine, St. Louis, MO

  • Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • National Cancer Centre Singapore, Singapore, Singapore

  • Istituto Europeo di Oncologia, Milano, Italy

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain

Locations

  • Canada

  • Italy

  • Netherlands

  • Singapore

  • Spain

  • Germany

  • Switzerland

  • Australia

  • United States

  • France

  • Belgium

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Alpelisib

  • BGJ-398

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01928459

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved